Structure via PubChem · Public domain (PubChem)
bemnifosbuvir
Sign in to saveAlso known as AT527, AT-511, AT-527
Bemnifosbuvir (AT-527, RO7496998) is an antiviral drug invented by Atea Pharmaceuticals and licensed to Roche for clinical development, a novel nucleotide analog prodrug originally developed for the treatment of hepatitis C. Bemnifosbuvir is the orally bioavailable hemisulfate salt of AT-511, which is metabolized in several steps to the active nucleotide triphosphate AT-9010, acting as an RNA polymerase inhibitor and thereby interfering with viral replication. Bemnifosbuvir has been researched for the treatment of coronavirus diseases such as that produced by SARS-CoV-2. It showed good results
In the Vinony graph
Vinony's link graph records 99 inbound references to bemnifosbuvir, and connects out to medication, influenza and SARS-CoV-2.
It sits within the topics Anti–RNA virus drugs, Chemical pages without DrugBank identifier and Drugs missing an ATC code.
Vinony links it to 6 Wikipedia language editions.
Chemical data
- Formula
- C24H33FN7O7P
- Molecular weight
- 581.5 g/mol
- IUPAC name
- propan-2-yl (2S)-2-[[[(3R,4R,5R)-5-[2-amino-6-(methylamino)purin-9-yl]-4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate
- SMILES
- C[C@@H](C(=O)OC(C)C)N[P@](=O)(OCC1[C@H]([C@@]([C@@H](O1)N2C=NC3=C(N=C(N=C32)N)NC)(C)F)O)OC4=CC=CC=C4
- InChIKey
- OISLSHLAXHALQZ-ZXWZJMKMSA-N
- XLogP
- 1.7
- Polar surface area
- 185 Ų
- H-bond donors
- 4
- H-bond acceptors
- 14
- Formal charge
- 0
via PubChem
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 581.216311246
- Has use
- medication
Show 4 more facts
- canonical SMILES
- CC(C)OC(=O)C(C)NP(=O)(OCC1C(C(C(O1)N2C=NC3=C(N=C(N=C32)N)NC)(C)F)O)OC4=CC=CC=C4
- isomeric SMILES
- C[C@@H](C(=O)OC(C)C)N[P@](=O)(OCC1[C@H]([C@@]([C@@H](O1)N2C=NC3=C(N=C(N=C32)N)NC)(C)F)O)OC4=CC=CC=C4
- chemical formula
- C₂₄H₃₃FN₇O₇P
- Commons category
- Bemnifosbuvir
via Wikidata · CC0
~1 min read
Encyclopedic overview
2 sectionsContents
- See also
- References
Bemnifosbuvir (AT-527, RO7496998) is an antiviral drug invented by Atea Pharmaceuticals and licensed to Roche for clinical development, a novel nucleotide analog prodrug originally developed for the treatment of hepatitis C. Bemnifosbuvir is the orally bioavailable hemisulfate salt of AT-511, which is metabolized in several steps to the active nucleotide triphosphate AT-9010, acting as an RNA polymerase inhibitor and thereby interfering with viral replication. Bemnifosbuvir has been researched for the treatment of coronavirus diseases such as that produced by SARS-CoV-2. It showed good results in early clinical trials but had inconsistent results at later stages. Bemnifosbuvir's Phase III study ended early as it failed to meet its primary endpoint of symptom alleviation and did not decrease viral load. However, the drug was well-tolerated and reduced relative hospitalization risk by 71%.
==See also== Galidesivir Remdesivir Lufotrelvir Molnupiravir Sofosbuvir
Excerpted from Wikipedia’s “bemnifosbuvir” article, available under the CC BY-SA 4.0 licence.